M

Marinomed Biotech AG
VSE:MARI

Watchlist Manager
Marinomed Biotech AG
VSE:MARI
Watchlist
Price: 41.8 EUR 1.7%
Market Cap: 34.7m EUR

Wall Street
Price Targets

MARI Price Targets Summary
Marinomed Biotech AG

Wall Street analysts forecast MARI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MARI is 52.02 EUR with a low forecast of 51.51 EUR and a high forecast of 53.55 EUR.

Lowest
Price Target
51.51 EUR
23% Upside
Average
Price Target
52.02 EUR
24% Upside
Highest
Price Target
53.55 EUR
28% Upside
Marinomed Biotech AG Competitors:
Price Targets
SUNPHARMA
Sun Pharmaceutical Industries Ltd
11% Upside
GS71
GSK plc
1% Upside
ZYDUSLIFE
Zydus Lifesciences Ltd
13% Upside
AFT
AFT Pharmaceuticals Ltd
19% Upside
600750
Jiang Zhong Pharmaceutical Co Ltd
21% Upside
COLL
Collegium Pharmaceutical Inc
2% Upside
002422
Sichuan Kelun Pharmaceutical Co Ltd
27% Upside
LUPIN
Lupin Ltd
13% Upside

Revenue
Forecast

Revenue Estimate
Marinomed Biotech AG

For the last 7 years the compound annual growth rate for Marinomed Biotech AG's revenue is 0%. The projected CAGR for the next 3 years is 38%.

0%
Past Growth
38%
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Marinomed Biotech AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat

Net Income
Forecast

Net Income Estimate
Marinomed Biotech AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MARI's stock price target?
Price Target
52.02 EUR

According to Wall Street analysts, the average 1-year price target for MARI is 52.02 EUR with a low forecast of 51.51 EUR and a high forecast of 53.55 EUR.

What is Marinomed Biotech AG's Revenue forecast?
Projected CAGR
38%

For the last 7 years the compound annual growth rate for Marinomed Biotech AG's revenue is 0%. The projected CAGR for the next 3 years is 38%.

Back to Top